This focused issue on “Mesothelioma: What We know and What We Do Not Know in 2020” is edited by Dr. Michele Carbone, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Dr. Michele Carbone is Professor of Pathology and served as Director of the University of Hawaii Cancer Center, a NCI-designated cancer center from 2009-2014, after being Interim Director from 2008-2009. Dr. Carbone worked at the National Institutes of Health (NIH) from 1986 to 1994, at the University of Chicago and Loyola University Cancer Center of Chicago rfom 1994 until 2006, when he joined the University of Hawaii Mānoa. Dr. Carbone has published over 150 peer-reviewed papers. His research has been funded through grants from the National Cancer Institute, American Cancer Society and the V-Foundation.
Focused issue outline:
- Biomarkers for mesothelioma: current status and future perspectives
- Diagnosis: different IHC markers help distinguish different mesothelioma histologies from benign and malignant conditions
- Epidemiology of mesothelioma in the 21st century in Europe and US, 40 years after restricted/banned asbestos use
- How asbestos and other fibers cause mesothelioma
- SV40 and mesothelioma 30 years later
- Mesothelioma genomics
- Epigenetic alterations in mesothelioma
- The BAP1 cancer syndrome: mechanisms and clinical implications
- Mesothelioma developing in carriers of inherited genetic mutations
- Chemotherapy Options versus “novel” therapies: how should we treat patients with Malignant Pleural Mesothelioma?
- Surgery for pleural mesothelioma: when it is indicated and why: different point of views (I)
- Surgery for pleural mesothelioma: when it is indicated and why: different point of views (II)
- Chromothripsis and creation of neoantigens in mesothelioma
- Immunotherapy for mesothelioma: a critical review of current clinical trials
- Peritoneal mesothelioma